USE OF H2A.Z.1 AS A HEPATOCELLULAR CARCINOMA BIOMARKER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jan 18, 2017
filing date -
Jan 19, 2016
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure relates to a use of H2AFZ as a hepatocellular carcinoma (HCC) biomarker and more particularly, to a marker for diagnosing hepatocellular carcinoma consisting of a H2AFZ gene or an expression protein H2A.Z.1 thereof, a composition for diagnosing or estimating prognosis of HCC, a method for diagnosing or estimating prognosis of HCC, a method of detecting a biomarker for diagnosing or estimating prognosis of HCC, a screening method of an HCC therapeutic agent, and a pharmaceutical composition for preventing or treating HCC. As it is verified that the expression level of the H2AFZ gene according to the present disclosure is increased in an HCC tissue or HCC cells compared to a non-HCC tissue or non-HCC cells, in the case of using the H2AFZ gene as the marker for diagnosing the HCC, the HCC can be rapidly and accurately diagnosed and predicted in early stages and the H2AFZ gene can be used as a target for developing a therapeutic agent for preventing or treating the HCC.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully